Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Britain orders 60 million Pfizer COVID-19 shots for booster programme

Published 28/04/2021, 17:21
Updated 28/04/2021, 19:10
© Reuters. FILE PHOTO: FILE PHOTO: Vials of the Pfizer-BioNTech vaccine against COVID-19

LONDON (Reuters) -Britain will buy 60 million more doses of Pfizer/BioNTech's COVID-19 vaccine, health minister Matt Hancock said, in a deal that more than doubles the country's supply of the shot ahead of a booster programme later this year.

Britain has now ordered a total of 100 million doses of the Pfizer (NYSE:PFE) vaccine, one of three COVID-19 shots being rolled out in the country.

Hancock said the shots had been secured to support a COVID-19 booster vaccination programme starting in the autumn, adding that the biggest risk to Britain's rollout so far was a new variant of the coronavirus.

"We're working on our plans for booster shots," Hancock said.

"These further 60 million doses will be used, alongside others, as part of our booster programme from later this year, so we can protect the progress that we've all made."

Earlier on Wednesday, Public Health England said the details of any booster programme were still being worked out, and it would be designed primarily with new variants in mind.

Britain's health ministry said data from trials using different combinations of COVID-19 vaccines would help determine the design of the programme.

England's Deputy Chief Medic Jonathan Van-Tam said that by mid to late-summer, millions of people would have had two shots of either the AstraZeneca (NASDAQ:AZN) or Pfizer vaccines, and the question then would be whether to give a different vaccine as a booster.

A study starting in June should provide answers, he said.

"We'll get an idea then of which gives you the highest boost, which perhaps gives you the broadest boost against a range of coronavirus variants, and indeed what the timings look like," he told a press conference.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"That is another reason why the vaccines taskforce has invested in contracts with not just one or two manufacturers, but six or seven so that we have that optionality."

Britain has administered 47.5 million vaccine doses so far, nearly 34 million of which are first shots.

While the country is second only to Israel in terms of the proportion of the population who have received a first dose, which stands at around 50%, it has suffered 127,000 deaths from COVID-19, the fifth-highest total globally.

Britain, which has a population of 67 million, has deals for 517 million doses of eight different COVID-19 vaccines, some of which remain under development.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.